Advanced Bladder Cancer VL

Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar

Details
The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...

ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH highlighting promising data from a different antibody-drug conjugate called sacituzumab govitecan (IMMU-132). There are a number of ongoing studies where sacituzumab govitecan which is being studied in advanced bladder cancer. Enfortumab vedotin targets Nectin-4, while sacituzumab govitecan is targeting Trop-2. Dr. Grivas highlights the final r...

ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks

Details
In this clinical conversation with Alicia Morgans, MD, MPH, and Joshua Meeks, MD, PhD we hear their clinical perspective combination therapies when treating metastatic urothelial carcinoma. They discuss several studies with recent data from the European Society for Medical Oncology Virtual Congress, (ESMO) 2020 including the KEYNOTE-361 the DANUBE trial, and the IMvigor130 data presented at earlie...

Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta

Details
Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...

The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo

Details
Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...

Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...

Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar

Details
Makarand Khochikar, President of the Urological society of India –West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj, joins Ashish Kamat, MD to discuss the case of a 70-year-old patient who presented with left-side loin pain and intermittent hematuria. An ultrasound and CT scan revealed a solid-lesion in the left kidney, lesions in the left...

Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas

Details
Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...

JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg

Details
Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...

Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki

Details
Ali Khaki and Petros Grivas come together to discuss a study Ali Khaki presented at the 2020 ASCO meeting, on the cost-effectiveness of atezolizumab added to first-line platinum chemotherapy for Advanced Urothelial Cancer. He with Dr. Grivas provides further insight into how this treatment plan was assessed, while also giving context regarding how cost-effectiveness is measured in cancer patients....